Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP
ST Segment Elevation Myocardial Infarction, Coronary Slow Flow Phenomenon
About this trial
This is an interventional treatment trial for ST Segment Elevation Myocardial Infarction focused on measuring STEMI, CSFP, Alprostadil, targeted perfusion microcatheter
Eligibility Criteria
Inclusion Criteria:
Patents with myocardial infarction who have symptom onset within 12h before randomization; ECG: ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads ; Corrected TIMI frame counted (cTFC) measured from the final angiographic imaging after PCI exceeding 40 frames; Signed informed consent form prior to trial participation.
Exclusion Criteria:
Coronary artery bypass surgery (CABG) history; Failed in stents implanting; Severe heart failure; Cardiogenic shock.
Sites / Locations
- Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
alprostadil
nitroglycerin
alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP